Short communication for targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches- part 2

Breast cancer is one of the common causes of death noticed in women globally. In order to find effective therapeutics, the current investigation has focussed on identifying candidate compounds for EGFR and HER2. Accordingly, the pharmacophore modelling approaches were adapted to identify two prospective compounds and were docked against the target 3RCD that is complexed with TAK-285 a known dual inhibitor. Focussing on the target 3RCD, our results have showed that the compounds have demonstrated a good binding affinity towards the target occupying the binding pocket. They have established key residue interactions with stable molecular dynamics simulation results. The Hit compounds have demonstrated a potential to penetrate the blood brain barrier thereby enriching their therapeutics towards breast cancer brain metastasis. Taken together, our findings propose two candidate compounds as EGFR/HER2 inhibitors that might serve as novel chemical spaces for designing and developing new inhibitors.

[1]  M. Hung,et al.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer , 2016, Cancer and Metastasis Reviews.

[2]  L. Dardenne,et al.  Receptor–ligand molecular docking , 2013, Biophysical Reviews.

[3]  A. Ohtsu,et al.  Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients , 2012, British Journal of Cancer.

[4]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[5]  T. Taniguchi,et al.  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. , 2011, Journal of medicinal chemistry.

[6]  Sugunadevi Sakkiah,et al.  3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. , 2010, European journal of medicinal chemistry.

[7]  C. Lovly,et al.  Mechanisms of receptor tyrosine kinase activation in cancer , 2018, Molecular Cancer.

[8]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[9]  Ruth Huey,et al.  Computational protein–ligand docking and virtual drug screening with the AutoDock suite , 2016, Nature Protocols.

[10]  Keun Woo Lee,et al.  Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches , 2018, Comput. Biol. Chem..

[11]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[12]  Marawan Ahmed,et al.  Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents , 2014, Journal of enzyme inhibition and medicinal chemistry.

[13]  Wen Shi,et al.  Risk Factors and Preventions of Breast Cancer , 2017, International journal of biological sciences.

[14]  M. Alsaid,et al.  Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers. , 2018, Bioorganic chemistry.

[15]  J. Kuriyan,et al.  Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. , 2011, Molecular cell.

[16]  Sugunadevi Sakkiah,et al.  Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors , 2012, Acta Pharmacologica Sinica.

[17]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[18]  Wei Zhang,et al.  EGFR / HER 2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by Pgp substrates in vitro and in vivo , 2015 .

[19]  VINCENT ZOETE,et al.  SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..

[20]  M. Bagiński,et al.  Docking simulations, Molecular properties and ADMET studies of novel Chromane­6,7­diol analogues as potential inhibitors of Mushroom tyrosinase , 2014 .

[21]  M. Ohba,et al.  Receptor Tyrosine Kinase-Targeted Cancer Therapy , 2018, International journal of molecular sciences.

[22]  R. M. de Angelo,et al.  Studies on the Dual Activity of EGFR and HER-2 Inhibitors Using Structure-Based Drug Design Techniques , 2018, International journal of molecular sciences.

[23]  Ying Zhang,et al.  Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. , 2016, European journal of medicinal chemistry.

[24]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors. , 2019, Pharmacological research.

[25]  Calvin Yu-Chian Chen,et al.  Ligand-Based and Structure-Based Investigation for Alzheimer's Disease from Traditional Chinese Medicine , 2014, Evidence-based complementary and alternative medicine : eCAM.

[26]  Dhiraj Kumar,et al.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges , 2018, Molecular Cancer.

[27]  Didier Rognan,et al.  Protein-Ligand-Based Pharmacophores: Generation and Utility Assessment in Computational Ligand Profiling , 2012, J. Chem. Inf. Model..

[28]  A. Alqahtani,et al.  Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers , 2019, Journal of enzyme inhibition and medicinal chemistry.

[29]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.

[30]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 ( HER 2 ) in Cancers : Overexpression and Therapeutic Implications , 2015 .

[31]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[32]  M. Moasser,et al.  The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.

[33]  Wei Zhang,et al.  EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo. , 2016, Oncology reports.

[34]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[35]  Peter Ertl,et al.  Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions , 2009, J. Cheminformatics.

[36]  Lina Chen,et al.  Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome , 2017, Oncology letters.

[37]  Susan Goodin,et al.  Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. , 2008, Clinical Therapeutics.

[38]  J. Lee,et al.  Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction , 2016, Oncotarget.